Rational Approach To Discover Multipotent Anti-Alzheimer Drugs
Journal of Medicinal Chemistry2004Vol. 48(2), pp. 360–363
Citations Over TimeTop 10% of 2004 papers
Michela Rosini, Vincenza Andrisano, Manuela Bartolini, María Laura Bolognesi, Patrizia Hrelia, Anna Minarini, Andrea Tarozzi, Carlo Melchiorre
Abstract
The coupling of two different pharmacophores, each endowed with different biological properties, afforded the hybrid compound lipocrine (7), whose biological profile was markedly improved relative to those of prototypes tacrine and lipoic acid. Lipocrine is the first compound that inhibits the catalytic activity of AChE and AChE-induced amyloid-beta aggregation and protects against reactive oxygen species. Thus, it emerged as a valuable pharmacological tool to investigate Alzheimer's disease and as a promising lead compound for new anti-Alzheimer drugs.
Related Papers
- → Inhibition of Acetylcholinesterase Activity in Human Brain Tissue and Erythrocytes by Galanthamine, Physostigmine and Tacrine(1991)97 cited
- → Acetylcholinesterase inhibition by tacrine analogues(1997)30 cited
- Development of the multi-target-directed acetylcholinesterase inhibitors based on tacrine(2008)
- [The effect of pH and reversible inhibitors on decarbamylation of acetylcholinesterase].(1991)
- → ChemInform Abstract: Hybrids of Oxoisoaporphine‐Tacrine Congeners: Novel Acetylcholinesterase and Acetylcholinesterase‐Induced β‐Amyloid Aggregation Inhibitors.(2011)